I overensstemmelse med virkningen på akut fase reaktanter var behandlingen med tocilizumab ledsaget af et fald i trombocyttallet inden for referenceintervallet.
Consistent with the effect on acute phase reactants, treatment with tocilizumab was associated with reduction in platelet count within the normal range.